Cipla Secures US FDA Approval for Ventolin, Analysts Forecast $100 Million Sales Potential
Cipla gains US FDA nod for Ventolin; analysts see $100 mn sales potential
Business Standard
Image: Business Standard
Cipla, an Indian pharmaceutical company, has received final approval from the United States Food and Drug Administration (US FDA) for its generic version of the albuterol inhaler, Ventolin. Analysts estimate this approval could lead to annual sales of approximately $100 million, bolstering Cipla's US market presence and overall revenue outlook.
- 01Cipla's generic Ventolin inhaler approval could generate $100 million in annual sales.
- 02Analysts have upgraded Cipla's stock rating to 'Buy' with a target price increase to ₹1,550.
- 03The approval addresses previous concerns about Cipla's US growth and revenue shortfalls.
- 04Cipla's US respiratory drug pipeline is expected to significantly enhance its market share.
- 05The company's India business is projected to contribute ₹12,600 crore to overall sales in FY26.
Advertisement
In-Article Ad
Cipla has secured final approval from the US Food and Drug Administration (US FDA) for its generic version of Ventolin HFA (Albuterol Sulfate), a widely used asthma inhaler. This approval is crucial for Cipla as it addresses growth concerns following the discontinuation of Lanreotide and loss of exclusivity for gRevlimid. Analysts estimate that the Ventolin inhaler, with a market size of approximately $1.5 billion, could yield annual sales of about $100 million for Cipla. Following this news, analysts at ICICI Securities upgraded Cipla's stock rating to 'Buy' and raised the target price to ₹1,550. The approval is expected to strengthen Cipla's US respiratory portfolio, which is a key focus area, particularly in complex inhalation products. Additionally, Cipla USA Inc. received approval for Nintedanib Capsules, further enhancing its product offerings. The company’s India business remains strong, projected to contribute 44% of its total sales in FY26, with a revenue CAGR of 10.3% expected over the next few years.
Advertisement
In-Article Ad
Cipla's approval for the generic Ventolin inhaler is expected to boost its revenue, which could translate into better pricing for asthma medications and improved access for patients in the US.
Advertisement
In-Article Ad
Reader Poll
Do you believe the approval of Cipla's generic Ventolin will improve access to asthma medications?
Connecting to poll...
More about Cipla
Read the original article
Visit the source for the complete story.